IBDEI0KP ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,10145,1,4,0)
 ;;=4^281.9
 ;;^UTILITY(U,$J,358.3,10145,1,5,0)
 ;;=5^Nutritional Anemia
 ;;^UTILITY(U,$J,358.3,10145,2)
 ;;=^123801
 ;;^UTILITY(U,$J,358.3,10146,0)
 ;;=281.0^^67^672^123
 ;;^UTILITY(U,$J,358.3,10146,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10146,1,4,0)
 ;;=4^281.0
 ;;^UTILITY(U,$J,358.3,10146,1,5,0)
 ;;=5^Vit B12 Deficiency (Pernicious Anemia)
 ;;^UTILITY(U,$J,358.3,10146,2)
 ;;=^7161
 ;;^UTILITY(U,$J,358.3,10147,0)
 ;;=282.60^^67^672^111
 ;;^UTILITY(U,$J,358.3,10147,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10147,1,4,0)
 ;;=4^282.60
 ;;^UTILITY(U,$J,358.3,10147,1,5,0)
 ;;=5^Sickle-Cell Anemia
 ;;^UTILITY(U,$J,358.3,10147,2)
 ;;=^7188
 ;;^UTILITY(U,$J,358.3,10148,0)
 ;;=282.62^^67^672^112
 ;;^UTILITY(U,$J,358.3,10148,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10148,1,4,0)
 ;;=4^282.62
 ;;^UTILITY(U,$J,358.3,10148,1,5,0)
 ;;=5^Sickle-Cell With Crisis
 ;;^UTILITY(U,$J,358.3,10148,2)
 ;;=^267982
 ;;^UTILITY(U,$J,358.3,10149,0)
 ;;=281.1^^67^672^124
 ;;^UTILITY(U,$J,358.3,10149,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10149,1,4,0)
 ;;=4^281.1
 ;;^UTILITY(U,$J,358.3,10149,1,5,0)
 ;;=5^Vit B12 Deficiency(Dietary)
 ;;^UTILITY(U,$J,358.3,10149,2)
 ;;=^267974
 ;;^UTILITY(U,$J,358.3,10150,0)
 ;;=286.7^^67^672^54
 ;;^UTILITY(U,$J,358.3,10150,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10150,1,4,0)
 ;;=4^286.7
 ;;^UTILITY(U,$J,358.3,10150,1,5,0)
 ;;=5^Coagulation Defect(Any),Acquired
 ;;^UTILITY(U,$J,358.3,10150,2)
 ;;=^2235
 ;;^UTILITY(U,$J,358.3,10151,0)
 ;;=289.9^^67^672^120
 ;;^UTILITY(U,$J,358.3,10151,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10151,1,4,0)
 ;;=4^289.9
 ;;^UTILITY(U,$J,358.3,10151,1,5,0)
 ;;=5^Thrombocytosis, Essential
 ;;^UTILITY(U,$J,358.3,10151,2)
 ;;=^55344
 ;;^UTILITY(U,$J,358.3,10152,0)
 ;;=451.9^^67^672^121
 ;;^UTILITY(U,$J,358.3,10152,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10152,1,4,0)
 ;;=4^451.9
 ;;^UTILITY(U,$J,358.3,10152,1,5,0)
 ;;=5^Thrombophlebitis 
 ;;^UTILITY(U,$J,358.3,10152,2)
 ;;=^93357
 ;;^UTILITY(U,$J,358.3,10153,0)
 ;;=446.6^^67^672^122
 ;;^UTILITY(U,$J,358.3,10153,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10153,1,4,0)
 ;;=4^446.6
 ;;^UTILITY(U,$J,358.3,10153,1,5,0)
 ;;=5^Thrombotic Thrombocytopenic Purpura(Ttp)
 ;;^UTILITY(U,$J,358.3,10153,2)
 ;;=^119061
 ;;^UTILITY(U,$J,358.3,10154,0)
 ;;=286.4^^67^672^125
 ;;^UTILITY(U,$J,358.3,10154,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10154,1,4,0)
 ;;=4^286.4
 ;;^UTILITY(U,$J,358.3,10154,1,5,0)
 ;;=5^Von Willebrand's Disease
 ;;^UTILITY(U,$J,358.3,10154,2)
 ;;=^127267
 ;;^UTILITY(U,$J,358.3,10155,0)
 ;;=204.00^^67^672^1
 ;;^UTILITY(U,$J,358.3,10155,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10155,1,4,0)
 ;;=4^204.00
 ;;^UTILITY(U,$J,358.3,10155,1,5,0)
 ;;=5^ALL w/o Remission
 ;;^UTILITY(U,$J,358.3,10155,2)
 ;;=^267521
 ;;^UTILITY(U,$J,358.3,10156,0)
 ;;=204.01^^67^672^3
 ;;^UTILITY(U,$J,358.3,10156,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10156,1,4,0)
 ;;=4^204.01
 ;;^UTILITY(U,$J,358.3,10156,1,5,0)
 ;;=5^ALL,In Remission
 ;;^UTILITY(U,$J,358.3,10156,2)
 ;;=^267522
 ;;^UTILITY(U,$J,358.3,10157,0)
 ;;=204.10^^67^672^16
 ;;^UTILITY(U,$J,358.3,10157,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10157,1,4,0)
 ;;=4^204.10
 ;;^UTILITY(U,$J,358.3,10157,1,5,0)
 ;;=5^CLL w/o Remission
 ;;^UTILITY(U,$J,358.3,10157,2)
 ;;=^267523
 ;;^UTILITY(U,$J,358.3,10158,0)
 ;;=204.11^^67^672^18
 ;;^UTILITY(U,$J,358.3,10158,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10158,1,4,0)
 ;;=4^204.11
 ;;^UTILITY(U,$J,358.3,10158,1,5,0)
 ;;=5^CLL,In Remission
 ;;^UTILITY(U,$J,358.3,10158,2)
 ;;=^267524
